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Objectives The aim of this study was to meta-analyze epidemiological studies and clinical trials that have assessed the ef-
fect of a Mediterranean diet on metabolic syndrome (MS) as well as its components.
Background The Mediterranean diet has long been associated with low cardiovascular disease risk in adult population.
Methods The authors conducted a systematic review and random effects meta-analysis of epidemiological studies and
randomized controlled trials, including English-language publications in PubMed, Embase, Web of Science, and
the Cochrane Central Register of Controlled Trials until April 30, 2010; 50 original research studies (35 clinical
trials, 2 prospective and 13 cross-sectional), with 534,906 participants, were included in the analysis.
Results The combined effect of prospective studies and clinical trials showed that adherence to the Mediterranean diet
was associated with reduced risk of MS (log hazard ratio: 0.69, 95% confidence interval [CI]: 1.24 to 1.16).
Additionally, results from clinical studies (mean difference, 95% CI) revealed the protective role of the Mediterra-
nean diet on components of MS, like waist circumference (0.42 cm, 95% CI: 0.82 to 0.02), high-density
lipoprotein cholesterol (1.17 mg/dl, 95% CI: 0.38 to 1.96), triglycerides (6.14 mg/dl, 95% CI: 10.35 to
1.93), systolic (2.35 mm Hg, 95% CI: 3.51 to 1.18) and diastolic blood pressure (1.58 mm Hg, 95% CI:
2.02 to 1.13), and glucose (3.89 mg/dl, 95% CI:5.84 to 1.95), whereas results from epidemiological
studies also confirmed those of clinical trials.
Conclusions These results are of considerable public health importance, because this dietary pattern can be easily adopted
by all population groups and various cultures and cost-effectively serve for primary and secondary prevention of
the MS and its individual components. (J Am Coll Cardiol 2011;57:1299–313) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.073The prevalence of the metabolic syndrome (MS) is increas-
ing rapidly throughout the world, in parallel with the
increasing prevalence of diabetes and obesity; thus, it is now
considered as a major public health problem (1). With the
National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III) definition, prevalence of the MS
in Europe, Asia, Australia, and North and South America
ranges between 9.6% and 55.7%; with the World Health
Organization (WHO) definition, prevalence ranges be-
tween 13.4% and 70.0%; and with the International Diabe-
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ens, Greece; †School of Medicine, University of Ioannina, Ioannina, Greece; and the
‡Department of Geriatrics and Metabolic Diseases, Second University of Naples,
Naples, Italy. All authors have reported that they have no relationships to disclose.Manuscript received May 24, 2010; revised manuscript received August 12, 2010,
accepted September 6, 2010.tes Federation definition, prevalence ranges between 7.4%
and 50% (2–4).
Regardless of the true actual figures, there is undoubtedly
a dramatic increase of this condition, and therefore, emerg-
ing action should be taken to prevent and control its
development. Lifestyle interventions, including dietary
changes and physical activity, play a crucial role in the
prevention of this condition (5). In fact, the NCEP ATP III
has already suggested dietary intervention to prevent this
epidemic. Diets rich in whole grain cereals, fruits, and
vegetables, with low animal-fat consumption, seem to
confer the prevention of cardiovascular disease risk factors,
like hypertension, hypercholesterolemia, and obesity (6).
The Mediterranean diet (MD) is a dietary pattern that has
already shown its cardioprotective effects. The MD was first
presented by Ancel Keys in the 1960s (7), and it is
characterized by high consumption of monounsaturated
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Mediterranean Diet and Metabolic Syndrome March 15, 2011:1299–313fatty acids, primarily from olives
and olive oil, and encourages
daily consumption of fruits, veg-
etables, whole grain cereals, and
low-fat dairy products; weekly
consumption of fish, poultry, tree
nuts, and legumes; a relatively
low consumption of red meat,
approximately twice/month; as
well as a moderate daily con-
sumption of alcohol, normally
with meals. The beneficial role of
the MD with regard to mortality
from all causes, cardiovascular
disease (CVD) and cancer (8), as
well as obesity and type 2 diabe-
tes (9,10) has already been reported from the results of many
epidemiological studies and clinical trials. Major bio-
pathophysiological mechanisms include antioxidant and
anti-inflammatory effects of the foods included in the
Mediterranean dietary pattern (9,11–17). However, the
influence of the MD on the development of the MS has
never been extensively studied. Thus, the aim of this work
was to perform a systematic review and a meta-analysis of
the findings of published original research articles in which
the investigators have assessed the effect of a Mediterranean
type of diet on the development of the MS as well as on its
components.
Methods
Data sources. Original research studies that were pub-
lished in English until April 30, 2010 were selected through
a computer-assisted published data search (i.e., PubMed,
Embase, Scopus, and the Cochrane Central Register of
Controlled Trials databases). Computer searches used com-
binations of Medical Subject Headings or other key words
relating to the aim of the study (i.e., MD, moderate fat diet,
monounsaturated fat diet, MS, syndrome X). Also, specific
searches were included: MD and high-density lipoprotein
(HDL)-cholesterol, MD and triglycerides, MD and blood
pressure, MD and glucose, MD and waist circumference. In
addition, the reference list of the retrieved articles was in
some cases used to find other articles relevant to the present
articles that were not allocated through the searching
procedure. The initial search resulted in 48 entries in
PubMed on MD and MS, 31 entries on MD and syndrome
X, 94 entries on MD and HDL cholesterol, 77 entries on
MD and triglycerides, 106 entries on MD and blood
pressure, 26 entries on MD and waist circumference, and 92
entries on MD and glucose. The relevance of studies was
assessed with a hierarchical approach on the basis of title,
abstract, and the full manuscript. For the reports that were
not fully available, a copy of the article was requested from
Abbreviations
and Acronyms
CVD  cardiovascular
disease
HDL  high-density
lipoprotein
HOMA-IR  Homeostatic
Model Assessment insulin
resistance
MD  Mediterranean diet
MS  metabolic syndrome
NCEP ATP III  National
Cholesterol Education
Program Adult Treatment
Panel IIIthe authors. gStudy selection. In total, 474 studies that evaluated the
effect of an MD on MS and its components were identified.
Exclusion criteria with regard to clinical trials included
studies that reported lack of randomization, lack of a control
diet group, comparison of the MD against the MD plus an
additional intervention or intervention without inclusion of
all the components of an MD and especially olive oil.
Observational studies and clinical trials not published in
English and studies that performed a post hoc analysis of
previously published studies—already selected for this
review—were also excluded. Thus, of the initial 474 studies
that were extracted from the search machines, 398 were
excluded on the basis of the title or abstract (i.e., irrelevant
research hypothesis studied). Of the remaining 76 studies,
24 were excluded for the following reasons: lacking a control
group (n  7), intervention of Mediterranean versus a
Mediterranean plus diet (n  5), not clear MD (n  6),
ritten in a language other than English (n  5), and
ost-hoc analysis (n  1). Therefore, 52 studies were
ligible for inclusion in the meta-analysis. Studies included
n the meta-analysis were those that had available results in
form that could be used for the present analysis. When it
as necessary, data in the required form were requested
rom the authors. Overall, 50 studies with a total of 534,906
articipants were finally included in this meta-analysis; of
hese, 2 were prospective, 13 were cross-sectional, and 35
ere clinical trials. In addition, for the meta-analysis of the
elected studies, the MOOSE (Meta-analysis Of Observa-
ional Studies in Epidemiology) and QUOROM (Quality
f Reporting of Meta-analyses) guidelines have been fol-
owed (18,19) (Fig. 1).
ata extraction. The following characteristics were ex-
racted from the original reports with a standardized data
xtraction form and included in the meta-analysis: design of
he study (clinical-trial, cross-sectional, or prospective co-
ort), lead author, year of publication, country of origin,
ample size, mean age and gender of participants, health
tatus, follow-up duration, effect size measurements (i.e.,
elative risk, odds ratio), and variables that entered into the
ultivariable model as potential confounding factors.
Two investigators (C.M.K., D.B.P.) collected the rele-
ant reports, whereas 2 other authors independently re-
iewed the published data (H.M., J.G.), and disagreements
ere solved by consensus and by the opinion of a fifth
uthor, if necessary. Outcomes of interest were development
r progression of the MS and changes in the levels of the
ain components of the MS: waist circumference (in cm),
DL cholesterol (in mg/dl), triglycerides (in mg/dl), sys-
olic and diastolic blood pressure (in mm Hg), as well as
lucose (in mg/dl). When the data were provided in other
nits (i.e., mmol/l), they were transformed into mg/dl for
onsistency of the results. Quality of studies was assessed
ccording to the number of participants, the duration of
ollow-up, and adjustment for potential confounders.
tudies with a high number of participants (i.e., 30/
roup for trials or 1,000 for observational), long dura-
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March 15, 2011:1299–313 Mediterranean Diet and Metabolic Syndrometion of follow-up (3 months for trials or 1 year for
observational), and adjustment for confounding factors
(including demographic, anthropometric, and traditional
risk factors) were considered to be of high quality. The
characteristics of the studies and the diet regimens are
shown in Tables 1 and 2.
tatistical analysis. Random effects meta-analysis of the
selected studies was applied on the basis of within-study
comparisons, thereby avoiding any biases being caused by
methodological differences between studies. Each study was
represented by a dummy variable, and the use of a random-
effects model was possible, because standard errors of the
point estimates within studies were provided by the inves-
tigators. With regard to the analysis for the MS, each data
point consisted of adherence to the MD and the odds ratio
or the relative risk (hazard ratio) of having the MS. The
estimated models used as dependent variables the (eventual)
presence or absence of MS. With regard to the analysis for
the components of the syndrome, each data point consisted
of adherence to the MD and the difference in mean values
and SD, of the group closer to the MD and the group away
from the diet for epidemiological studies, while for clinical
trials of the difference in mean values and SD after the
intervention and at baseline, in the intervention and the
control group. The validity of the models was examined
with the influence of each separate data point (i.e., study) on
the estimated regression coefficients. The latter was assessed
with the use of Cook’s distance to detect possible outliers.
Heterogeneity was assessed with Cochran’s Q and I2
(I2 ranges between 0% and 100%, with lower values repre-
enting less heterogeneity) and evaluated with the chi-
quare test. To examine the source of heterogeneity, sensi-
ivity analyses were performed according to some
haracteristics of the studies, such as: country of origin
Mediterranean or not), follow-up time (below or above the
edian of the clinical trials [i.e., 3 months]), number of
articipants in clinical trials (below or above the median size
i.e., 66 participants]), recommendation regarding physical
ctivity (yes or no), and quality of intervention (i.e., clinical
rials with 30 participants and duration of follow-up 3
onths or not). To assess the presence of publication bias,
he “funnel plot” was tested. All statistical calculations were
erformed in NCSS 2004 software (Number Cruncher
tatistical Systems, Kaysville, Utah).
esults
ample sizes of the 15 observational studies that were
ncluded in the meta-analysis varied between 328 and
97,308 and, for the 35 clinical trials, varied between 8 and
,224 participants; 35 of the selected studies were conducted
n Mediterranean populations, 6 were performed in U.S.
opulations (20–25), 7 were performed in northern Euro-
ean populations (26–32), 1 was performed in a European
opulation (Mediterranean and non-Mediterranean) (33),
nd 1 was performed in an Australian population (34).D and MS. Eight studies with 10,399 subjects evaluated
he role of the MD on the development or progression of
he MS. Five of these 8 studies (35–39) reported a beneficial
ffect of compliance with the MD, as compared with the
ontrol diet (i.e., low-fat diet or usual care) or with low
dherence to the Mediterranean dietary pattern. Overall,
dherence to the MD was associated with a beneficial effect
ith regard to the MS in 2 of 2 clinical trials, in 1 of 2
rospective studies, and in 2 of 4 cross-sectional studies, as
ompared with lower compliance with this pattern or with a
ontrol diet (i.e., low-fat diet or usual care) (Fig. 2). The
ombined effect of both clinical trials and prospective
tudies was highly protective (log-hazard ratio  0.69,
5% CI: 1.24 to 1.16), whereas the combined effect of
ross-sectional studies was not significant (log-odds ratio 
0.16, 95% CI: 0.49 to 0.17). No publication bias was
bserved as indicated by the funnel plot (not presented
ere).
D andMS components. WAIST CIRCUMFERENCE LEVELS.
Three cross-sectional studies (20,33,40) reported a benefi-
cial effect of close adherence to the MD, as compared with
low adherence (Table 3). Heterogeneity of the effect measures
regarding waist circumference was observed [Cochran’s Q 
28.32(4), p 0.001, I2 99.4%]. Moreover, 11 clinical trials
with 1,646 subjects (997 assigned to an MD, and 669 assigned
to a control diet) evaluated the role of adherence to the MD on
waist circumference. Overall, adherence to the MD was
associated with a beneficial effect with regard to waist circum-
ference as compared with the control diet (Table 4); but, it
should be noted that the previous finding was mainly attributed
to 1 study (21) that found a beneficial effect of the MD, as
compared with the control diet. No significant heterogeneity of
the effect measures regarding waist circumference [Cochran’s
Q  8.23(13), p  0.83, I2   0%] was observed.
LIPIDS LEVELS. Three studies (14,20,40) reported a bene-
ficial effect of close adherence to the MD on HDL cholesterol
levels, as compared with low adherence. Overall, adherence
to the MD was associated with higher HDL-cholesterol
levels as compared with the control diet (Table 3). Heter-
ogeneity of the effect measures was observed [Cochran’s Q
 52.78(6), p  0.001, I2  88.6%]. Moreover, 29 clinical
rials with 3,822 subjects (2,202 assigned to an MD, and
,903 assigned to a control diet) examined the effect of
dherence to the MD on HDL-cholesterol. Seven studies
31,39,41–45) reported a beneficial effect of an MD, as
ompared with the control diet, whereas 2 studies reported
beneficial effect of a high saturated fat diet as compared
ith the MD (46,47). Overall, adherence to the MD was
ssociated with higher HDL-cholesterol levels as compared
ith the control diet (Table 4). Heterogeneity of the effect
easures was observed [Cochran’s Q  109.99(40), p 
.001, I2  63.6%].
Concerning triglycerides, 3 observational studies (14,40,48)
reported a beneficial effect of MD, as compared with low
adherence to this traditional pattern. Overall, adherence to the
Characteristics of Observational Studies That Evaluated Effect of MD on Development of MS and/or its ComponentsTable 1 Characteristics of Observational Studies That Evaluated Effect of MD on Development of MS and/or its Components
First Author (Ref. #) Country, Year n Age (yrs), Sex Health Status MD Assessment Tool MS Adjustments
Prospective studies (n  2)
Tortosa et al. (35) Spain, 2007 2,563 20–90, M/F No CVD risk factors MDS IDF Age, sex, PA, smoking, total energy intake
Rumawas et al. (25) U.S., 2009 1,932 Mean 54, M/F Without DM Free of MS MSDPS NCEP ATP III Age, sex, BMI at baseline energy intake, smoking,
BMI change
Cross-sectional studies (n  14)
Psaltopoulou et al. (17) Greece, 2004 20,343 20–86, M/F Without hypertension MDS — Age, sex, place of residence, education, BMI,
waste-to-hip ratio, energy, PA
Panagiotakos et al. (38) Greece, 2004 2,282 18, M/F General population MDS NCEP ATP III Age, sex, PA, education, smoking, apoA1, apoB, WBC,
LDL, CRP, Lp-a, homocysteine, fibrinogen, amyloid A
Chrysohoou et al. (14) Greece, 2004 3,042 18, M/F General population MedDietScore — —
Mantzoros et al. (20) U.S., 2006 987 30–55, F Diabetic Women MDS — —
Alvarez-Leon et al. (66) Spain Canary
Islands, 2006
578 18, M/F General population Specific 10-item score NCEP ATP III Age, sex, PA, education, smoking, BMI, diet in the
past 12 months, energy intake
Bach-Faig et al. (67) Spain, 2006 328 18–75, M/F General population MDS or score by
Sanchez-Villegas et al. (77)
— —
Tzima et al. (40) Greece, 2007 1,762 18, M/F Overweight and obese MedDiet Score — —
Panagiotakos et al. (52) Greece, 2007 3,042 18, M/F General population MedDiet Score — —
di Giuseppe et al. (68) Italy, 2008 522 18–96, M/F General population MAI — —
Nunez-Cordoba et al. (50) Spain, 2008 9,408 20–90, M/F University graduates MDS
Esposito et al. (69) Italy, 2009 901 35–70, M/F Type 2 Diabetes MDS — —
Romaguera et al. (33) Europe, 2009 497,308 25–70, M/F General population MDS — —
Babio et al. (36) Spain, 2009 808 (prior CVD) Mean 67, M/F Prior CVD 14-point questionnaire NCEP ATP III Age, sex, PA, smoking, energy intake
Doupis et al. (70) Greece, 2009 832 17–39, M Healthy young, navy recruits MedDiet Score IDF, NCEP ATP III Age, smoking, PA, marital status, coffee
consumption, family history of DM and CHD,
biochemical measurements
Observational studies (n  16).
apo apolipoprotein; BMI body mass index; CHD coronary heart disease; CVD cardiovascular disease; DM diabetes mellitus; IDF definition of the MS according to the International Diabetes Federation (76); LDL low-density lipoprotein; MAIMediterranean
adequacy index (74); MDMediterranean diet; MDSMediterranean diet scale (range 0 to 9) (71); MedDietScoreMediterranean diet score (range 0 to 55) (72); MSmetabolic syndrome; MSDPSMediterranean style dietary pattern score (73); NCEP ATP III definition
of the metabolic syndrome according to the National Cholesterol Education Program Adult Treatment Panel III (75); PA  physical activity.
1302
Kastorinietal.
JACC
Vol.57,No.11,2011
M
editerranean
Diet
and
M
etabolic
Syndrom
e
M
arch
15,2011:1299–313
Characteristics of Clinical Trials That Evaluated Effect of MD on Development of MS and/or Its ComponentsTable 2 Characteristics of Clinical Trials That Evaluated Effect of MD on Development of MS and/or Its Components
First Author (Ref. #) Country, Year
Sample Size
Control
Intervention Age (yrs), Sex Health Status MD Intervention Duration MS, Adjustments
Barzi et al. (48)
Use of cross-sectional, baseline data
Italy, 2003 11,246
2,811
2,811
19–90, M/F Post-MI patients — — —
De Lorgeril et al. (64) France, 1994 605
303
302
70, M/F Post-MI Bread, root and green vegetables, fish, less red meat,
daily fruits intake, fats replaced with margarine
supplied by the study
5 yrs —
Castro et al. (62) Spain, 2000 22
22
22
Mean 23, M Healthy
normolipidemic
15% Pro, 45% CHO, 40% fat (10% SF, 22% MUFA,
8% PUFA), chol 285–300 mg
4 weeks*3 —
Mc Manus et al. (21) U.S., 2001 101
51
50
18–70, M/F Overweight and
obese, no chronic
disease
35% energy from fat, SF 5%, MUFA 15%–20%, PUFA
10%, Pro 15–20%, CHO 45%–50%, chol 200 mg,
fiber 25 g
18 months —
Perez-Jimenez et al. (59) Spain, 2001 59
59
59
30
Mean 23, M/F
Healthy young 15% Pro, 47% CHO, 38% fat (10% SFA, 22% MUFA,
6% PUFA)
28 days*3 —
Fuentes et al. (57) Spain, 2001 22
22
22
18–65, M Hypercholesterolemic 5% Pro, 47% CHO, 38% fat (10% SFA, 22% MUFA,
75% of which from extra virgin olive oil,
6% PUFA)
28 days*3 —
Singh et al. (26) UK, 2002 56
18
18
57–80, M/F Healthy older subjects Increase fruits and vegetables, red meat replaced by
poultry and fish, butter and cream replaced by
margarine and use of olive oil
6 weeks —
Jula et al. (16) Finland, 2002 120
60
60
38–64, M Hypercholesterolemic Energy intake from SF plus trans fat 10%, replace
with MUFA and PUFA, chol 250 mg, increase
intake of fruits, vegetables, soluble fiber
12 weeks —
Esposito et al. (41) Italy, 2003 120
60
60
20–46, F Pre-menopausal and
obese
CHO: 50%–60%, Pro: 15-20%, FAT: 30%, SF: 10%,
MUFA: 10%–15%, PUFA: 5%–8%,
Fiber: 18 g/1,000 kcal
2 yrs —
Sondergaard et al. (27) Denmark, 2003 131
63
68
18–80, M/F IHD,
hypercholesterolemic
600 g of fruits and vegetables daily, reduce intake of
fat, eat fatty fish at least once a week, eat bread
and cereals, and to replace refined, hard, animal
margarine products with canola oil
1 yr —
Toobert et al. (22) U.S., 2003 279
116
163
75, F Post-menopausal with
DM
Increase: bread, root vegetables, green vegetables,
legumes, fish, poultry, fruit, olive oil, canola oil,
commercially available olive oil-canola oil–based
margarine. Decrease: red meat, butter, cream
6 months —
Rodriguez-Villar et al. (55) Spain, 2003 22
22
22
Mean 61, M/F Type 2 diabetes 15% Pro, 40% CHO, 40% fat, 10% SF, 25% MUFA,
olive oil: 25% energy)—only whole grain products.
Limitation of red meat, eggs, whole fat dairy products,
emphasis on vegetables and fish
6 weeks
6 weeks
—
Piers et al. (34) Australia, 2003 8
8
8
24–49, M Overweight and obese Olive oil, nuts, avocados 41.9% CHO, 40.1% fat
(11% SF, 22.3% MUFA), fiber 3.4 g/MJ
4 weeks
4 weeks
—
Fernandez de la Puebla et al. (61) Spain, 2003 34
34
34
18–63, M Hypercholesterolemic 15% Pro, 47% CHO, 38% fat (10% SFA, 22% MUFA,
75% of which from olive oil, 6% PUFA)
28 days*3 —
Ambring et al. (28) Sweden, 2004 22
22
22
31–51, M/F Healthy subjects 2 dietary fiber, 3 more PUFA and -3, less than
one-half of the SF, 3 less cholesterol and 35%
decrease in glycemic index, 2 g/day sterol esters,
10 g of alcohol/day
4 weeks
4 weeks
4 weeks
Wash out
—
(Continued on next page)
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First Author (Ref. #) Country, Year
Sample Size
Control
Intervention Age (yrs), Sex Health Status MD Intervention Duration MS, Adjustments
Gerhard et al. (23) U.S., 2004 11
11
11
Mean 50.4,
M/F
Type 2 diabetes High-MUFA: 40% fat (26% MUFA), 45% CHO 6 weeks
6 weeks
6–12 weeks
Wash out
—
Bravo-Herrera et al. (47) Spain, 2004 41
41
41
Mean 23.4,
M/F
Healthy young 15% Pro, 47% CHO, 38% fat (10% SFA,
22% MUFA—80% from virgin olive oil, 6% PUFA)
28 days*3 —
Esposito et al. (39) Italy, 2004 180
90
90
Mean 44, M/F MS At least 250–300 g fruits, 125–150 g vegetables,
25–50 g walnuts, 400 g whole grains, increase
consumption of olive oil
CHO: 50%–60%, Pro: 15%–20%, FAT: 30%,
SF: 10%, Chol: 300 g/day
2 yrs NCEP ATP III age, sex,
body weight
change, drug use,
associated
diseases
Gomez et al. (46) Spain, 2005 16
16
16
30
Mean 21, M
Healthy
normolipidemic
15% Pro, 47% CHO, 38% fat (10% SFA, 22% MUFA,
75% of which from extra virgin olive oil, 6% PUFA)
28 days*3 —
Vincent-Baudry et al. (56) France, 2006 212
110
102
18–70, M/F Moderate CVD risk Nuts, whole meal bread, cereals, raw and cooked
fruits and vegetables, legumes, olive oil as the
main source of fat, fish 4/week, red meat
1 time/week, sheep and poultry the main source of
meat, cheeses mainly from sheep and goat, alcohol
1 glass for women, 2 glasses for men
(FAT 35%–38%, MUFA: 50%, PUFA: 25%, SF: 25%,
25 g fiber)
3 months —
Michalsen et al. (29) Germany, 2006 101
53
48
Mean 59.4,
M/F
Established and
treated CAD
5 fruits and vegetables/day, emphasis on root and
green vegetables, 2 portions fatty fish/week,
whole grains, flaxseed and nuts recommended,
3 servings/week meat replaced by poultry, fish or
vegetarian dishes, olive oil, canola oil mainly,
walnut and flaxseed oil for some dishes, margarine
discouraged, modest red wine consumption with
meals
1 yr —
Bellido et al. (58) Spain, 2006 20
20
20
Mean 23, M Healthy young 15% Pro, 47% CHO, 38% fat (10% SFA, 22%
MUFA—80% from virgin olive oil, 6% PUFA)
28 days*3 —
Estruch et al. (42) Spain, 2006 772
257
257,258
55–80, M/F High CVD risk Instructions to increase the 14-item Mediterranean score
MD-virgin olive oil: free provision of olive oil
MD-mixed nuts: free provision of nuts
3 months —
Paniagua et al. (53) Spain, 2007 11
11
11
35–75, M/F Obese and type 2
diabetes
15% Pro, 47% CHO, 38% fat 9% SFA, 23% MUFA—
75% from extra virgin olive oil, 6% PUFA)
28 days*3 —
Lindeberg et al. (32) Sweden, 2007 29
15
14
Pal 67
Med 57, M
IHD and Glu
intolerance or DM
Whole-grain cereals, low-fat dairy products, potatoes,
legumes, vegetables, fruits, fatty fish and refined
fats rich in monounsaturated fatty acids and alpha-
linolenic acid
3 months —
(Continued on next page)
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ContinuedTable 2 Continued
First Author (Ref. #) Country, Year
Sample Size
Control
Intervention Age (yrs), Sex Health Status MD Intervention Duration MS, Adjustments
Perez-Martinez et al. (60) Spain, 2007 16
16
16
M Healthy 15% Pro, 47% CHO, 38% fat, 10% SF, 24% MUFA,
4% PUFA
4 weeks*3 —
Salas-Salvado et al. (37) Spain, 2008 1,224
422
419/423
Older, M/F High CVD risk Instructions to increase the 14-item Mediterranean score
MD-virgin olive oil: free provision of olive oil
MD-mixed nuts: free provision of nuts
1 yr NCEP ATP III age, sex,
baseline obesity
status, weight
changes
Papadaki and Scott (31) Scotland, 2008 72
19
53
25–55, F Healthy The intervention aimed depending on participants
current dietary intake to encourage by e-mail to
attempt increasing the consumption of vegetables,
fruits-nuts-seeds, legumes, and MUFA/SFA ratio
6 months —
Tuttle et al. (24) U.S., 2008 101
50
51
Mean 58,
M/F
Post-MI Omega-3 (0.75% kcal), MUFA (20%–25% kcal);
emphasis on the increased consumption of cold
water fish (3–5/week), oils from olives, canola,
and soybeans
2 yrs —
Shai et al. (49) Israel, 2008 322
104,109
109
40–65, M/F Moderately obese 1,500 kcal for women, 1,800 kcal for men, 35% fat,
30–45 g of olive oil and 20 g nuts daily
Rich in vegetables, low in red meat with poultry and
fish replacing beef and lamb
2 yrs —
Rallidis et al. (51) Greece, 2009 90
44
46
70, M/F Abdominal obesity no
CVD or DM
Daily consumption of whole wheat grains and
products, 2–3 portions of low-fat dairy, 2 salads
(1 of which should contain2 tomatoes), 3 fruits,
concentrated fruit juice without preservatives, 5 ml
olive oil-based margarine, extra virgin olive oil as
the main source of fat, 45 ml, 6 whole raw
almonds, 150 ml red wine, 1 portion of
fish/week, 1 portion red meat/week
2 months —
Buscemi et al. (63) Italy, 2009 20
10
10
30–50, F Overweight and
obese
MD: fatty fish 3 servings/week, unrefined grain,
nuts (15 g/day), legumes (40 g/day), red wine
(1 glass/day)—80 g Pro
2 months —
Bos et al. (30) the Netherlands, 2009 60
20
20
40–65, M/F No DM, with mild
abdominal obesity
Rich in extra virgin olive oil higher intake of vegetables
(250 g MD, 200 g high-MUFA diet) fruits (3 MD,
1 high-MUFA diet), lower intake of dairy products
(224 g MD, 360 g high-MUFA diet, red meat
(64 g MD, 84 g high-MUFA diet)
2 months —
Esposito et al. (43) Italy, 2009 215
107
108
30–75, M/F Overweight
New DM
50% from complex CHO, 30% fat, 30–50 g from
olive oil. Diet rich in vegetables and whole grains,
low in red meat, which was replaced with poultry
and fish
4 yrs —
Athyros et al. (44) Greece, 2009 150
50
50
Mean 55,
M/F
Mildly
hypercholesterolemic
7-day menus that incorporated the salient
characteristics of the MD
4 months —
Elhayany et al. (45) Israel, 2009 179
55
63,61
30–65, M/F Overweight with DM TM: 20% Pro, 50% CHO, 30% fat, 7% SF, 10% MUFA,
12% PUFA, fiber 30 g
LCM: 20% Pro, 35% CHO, 45% fat, 7% SF,
23% MUFA, 15% PUFA, fiber 30 g
1 yr —
Clinical trials (n  36).
chol cholesterol; CHO carbohydrates; IHD ischemic heart disease; LCM low-carbohydrate Mediterranean diet; MImyocardial infarction; MUFAmonounsaturated fatty acids; Pro protein; PUFA polyunsaturated fatty acids; SF saturated fat; SFA saturated
fatty acids; TM  traditional Mediterranean diet; other abbreviations as in Table 1.
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Results From Observational Studies That Evaluated the Effect of MD on Components of MSTable 3 Results From Observational Studies That Evaluated the Effect of MD on Components of MS
First Author (Ref. #)
Waist Circumference
(cm)
HDL Cholesterol
(mg/dl)
Triglycerides
(mg/dl)
Systolic BP
(mm Hg)
Diastolic BP
(mm Hg)
Glucose
(mg/dl) HOMA-IR
Cross-sectional studies
Chrysohoou et al. (14), men 3.00 (1.46 to 4.54) 7.00 (15.76 to 1.76) 4.00 (6.09 to1.91) 3.00 (4.35 to1.65) 3.00 (6.40 to 0.40)
Chrysohoou et al. (14), women 5.00 (3.58 to 6.42) 8.00 (15.53 to0.47) 9.00 (11.28 to6.72) 5.00 (6.30 to3.70) 3.00 (6.40 to 0.40)
Mantzoros et al. (20) 5.30 (8.15 to2.45) 2.70 (0.01. to 5.39) 26.30 (56.75 to 4.15)
Bach-Faig et al. (67) 3.44 (0.91 to 7.79) 7.03 (23.17 to 9.11)
Tzima et al. (40) 24.2 (26.15 to22.25) 2.30 (2.22 to 2.38) 17.0 (18.85 to15.15) 3.00 (3.18 to2.82) 7.00 (7.18 to6.82) 6.00 (6.34 to5.66) 0.40 (0.42 to0.38)
Panagiotakos et al. (52),
diabetes mellitus or IFG
23.00 (30.59 to15.41) 2.20 (2.50 to1.90)
Panagiotakos et al. (52) 6.00 (7.24 to4.76) 0.40 (0.45 to0.35)
di Giuseppe et al. (68), men 0.00 (6.45 to 6.45) 0.00 (3.48 to 3.48) 2.00 (1.37 to 5.37)
di Giuseppe et al. (68), women 9.00 (1.98 to 16.01) 1.00 (2.34 to 4.34) 0.00 (3.05. to 3.05)
Nunez-Cordoba et al. (50) 1.80 (0.96 to 2.64) 0.50 (0.11 to 1.10)
Esposito et al. (69) 0.70 (2.85 to 1.45) 0.00 (1.61 to 1.61) 8.86 (19.64 to 1.92) 1.80 (5.97 to 9.57)
Barzi et al. (48) 0.60 (0.01 to 3.07) 5.00 (9.39 to0.61)
Romaguera et al. (33), men 0.80 (0.93 to0.67)
Romaguera et al. (33), women 1.60 (1.70 to1.50)
Combined effect 5.78 (7.26 to4.31) 2.25 (1.15 to 3.34)* 9.88 (16.05 to3.71)* 1.81 (4.83 to 1.21) 2.36 (6.12 to 1.39) 3.93 (6.25 to1.61)* 0.87 (1.15 to0.59)*
Prospective studies
Tortosa et al. (35) 0.50 (1.96 to 0.96) 0.30 (1.77 to 2.37) 2.00 (6.74 to 2.74) 0.80 (0.84 to 2.44) 0.90 (0.38 to 2.18) 1.20 (0.53 to 2.93)
Data are presented as mean difference between highest versus lowest category of diet score (95% confidence interval). *Significant associations.
BP  blood pressure; HDL  high-density lipoprotein; HOMA-IR  Homeostatic Model Assessment insulin resistance; other abbreviations as in Table 1.
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March 15, 2011:1299–313 Mediterranean Diet and Metabolic SyndromeMD was associated with lower triglycerides levels (Table 3).
Heterogeneity of the effect measures regarding triglycerides
levels was observed [Cochran’s Q 33.18(6), p 0.001, I2
81.9%]. In addition, 29 clinical trials with 3,822 subjects (2,202
assigned to an MD, and 1,903 assigned to a control diet)
examined the relationship between compliance with the Med-
iterranean dietary pattern and triglycerides levels. Five studies
(39,42,43,45,49) reported a beneficial effect of an MD, as
compared with the control diet, whereas the rest of the studies
observed no significant differences. Overall, adherence to the
MD was associated with lower triglyceride levels as compared
with the control diet (Table 4). Heterogeneity of the effect
measures regarding triglyceride levels [Cochran’s Q 
89.50(40), p  0.001, I2  55.3%] was also evident.
BLOOD PRESSURE LEVELS. Five observational studies with
5,535 participants were included in the analysis. Two
tudies (14,40) reported a beneficial effect of close adherence
o the MD on systolic blood pressure, as compared with low
dherence, whereas 1 study showed higher systolic blood
ressure levels for the group more closely following the MD
50). Overall, adherence to the MD was not associated with
ystolic blood pressure levels, as compared with the control
iet (Table 3). Heterogeneity of the effect measures regard-
ng systolic blood pressure levels was also observed [Co-
hran’s Q  161.28(5), p  0.001, I2  96.8%]. Moreover,
14 clinical trials with 3,060 subjects (1,632 assigned to an
MD, and 1,436 assigned to a control diet) evaluated the
effect of the MD on systolic blood pressure levels. Three
f the metabolic syndrome (squares and diamonds represent effect size;
iet was associated with a protective effect in 2 of 2 clinical trials, 2 of 4 cross-
ith this pattern or with a control diet. The combined effect of both clinical trials
o 1.16). *Log(odds ratio) or log(relative risk).Figure 1 Process of Study Selection
Studies (n  474) that evaluated the effect of a Mediterranean diet on metabolic
syndrome and its components were identified. After exclusions, 50 studies were
finally included in the meta-analysis.Figure 2 Mediterranean Diet and Metabolic Syndrome
Forest plot of studies that evaluated the effect of Mediterranean diet on the presence o
extended lines show 95% confidence intervals [CIs]). Adherence to the Mediterranean d
sectional studies, and 1 of 2 prospective studies, as compared with lower compliance w
and prospective studies was highly protective (log-hazard ratio: 0.69, 95% CI: 1.24 t
Results From Clinical Trials That Evaluated Effect of MD on Components of MSTable 4 Results From Clinical Trials That Evaluated Effect of MD on Components of MS
First Author (Ref. #) WC (cm) HDL Cholesterol (mg/dl) Triglycerides (mg/dl) Systolic BP (mm Hg) Diastolic BP (mm Hg) Glucose (mg/dl) HOMA-IR
De Lorgeril et al. (64) 1.16 (3.58 to 1.26) 19.49 (44.62 to 5.65) 2.00 (4.77 to 0.77) 1.00 (3.77 to 1.77)
Castro et al. (NCEP) (62) 3.87 (2.03 to 5.71) 0.00 (16.44 to 16.44)
Castro et al. (sunflower) (62) 1.55 (0.46 to 2.63) 2.66 (12.02 to 17.33)
Mc Manus et al. (21) 4.20 (7.99 to0.41)
Perez-Jimenez et al. (SF) (59) 3.48 (7.38 to 0.41) 1.77 (7.92 to 11.46) 1.80 (3.94 to 0.34)
Perez-Jimenez et al. (CHO) (59) 1.55 (1.98 to 5.08) 0.89 (8.03 to 9.80) 1.44 (3.74 to 0.86)
Fuentes et al. (SF) (57) 1.00 (6.15 to 4.15) 9.00 (17.33 to 35.33)
Fuentes et al. (NCEP) (57) 1.00 (4.09 to 6.09) 9.00 (29.58 to 11.58)
Singh et al. (26) 8.00 (4.99 to 20.99) 1.00 (5.50 to 7.50)
Esposito et al. (41) 8.00 (3.66 to 12.34) 11.00 (27.00 to 4.99) 1.00 (3.95 to 1.95) 1.70 (3.39 to0.01) 7.00 (11.62 to2.38) 0.90 (1.05 to0.75)
Sondergaard et al. (27) 0.77 (4.31 to 5.86) 5.31 (34.11 to 23.49)
Toobert et al. (22) 0.96 (1.74 to 3.66) 11.9 (40.31 to 16.51) 0.33 (3.06 to 3.72) 1.70 (3.84 to 0.44)
Rodriguez-Villar et al. (55) 0.00 (4.56 to 4.56) 1.55 (9.14 to 6.05) 2.66 (54.24 to 59.55) 18.00 (12.20 to 48.20)
Piers et al. (34) 3.10 (11.49 to 5.29) 3.87 (11.21 to 3.47) 0.00 (96.16 to 96.16) 8.80 (20.89 to 3.29) 5.90 (14.65 to 2.85) 1.80 (11.95 to 8.35)
de la Puebla et al. (SF) (61) 1.00 (5.16 to 3.16) 9.00 (34.85 to 52.85)
de la Puebla et al. (CHO) (61) 1.00 (3.11 to 5.11) 9.00 (48.38 to 30.38)
Ambring et al. (28) 0.00 (11.07 to 11.07) 17.71 (43.04 to 7.62) 1.80 (3.35 to 6.95)
Gerhard et al. (23) 1.00 (6.34 to 8.34) 18.0 (123.8 to 87.85) 6.00 (22.83 to 34.83)
Bravo-Herera et al. (ctr) (47) 2.32 (1.08 to 5.72) 0.89 (9.86 to 11.64)
Bravo-Herera et al. (SF) (47) 3.87 (7.62 to0.11) 5.31 (5.44 to 16.06)
Esposito et al. (39) 2.00 (4.73 to 0.73) 3.00 (0.28 to 5,72) 19.00 (34.67 to3.34) 3.00 (5.73 to0.27) 2.00 (3.77 to0.23) 6.00 (8.79 to3.21) 1.10 (1.30 to0.90)
Gomez et al. (ctr) (46) 3.10 ( to 5.29 to 11.48) 4.43 (28.46 to 19.61)
Gomez et al. (SF) (46) 13.93 (21.65 to6.22) 9.74 (32.13 to 12.64)
Vincent-Baudry et al. (56) 0.00 (5.58 to 5.58) 0.00 (23.73 to 23.73) 1.00 (3.34 to 5.34) 2.00 (1.69 to 5.69) 0.00 (3.42 to 3.42) 0.00 (0.49 to 0.49)
Michalsen et al. (29) 1.94 (2.88 to 6,75) 3.54 (35.23 to 28.15)
Bellido et al. (SF) (58) 3.87 (8.64 to 0.89) 5.31 (14.39 to 25.02)
Bellido et al. (CHO) (58) 2.71 (1.76 to 7.18) 4.43 (15.56 to 24.42)
Estruch et al. (nuts) (42) 0.08 (0.97 to 1.13) 1.31 (0.14 to 2.48) 10.00 (19.37 to0.63) 7.14 (9.98 to4.30) 2.75 (4.20 to1.30) 6.00 (11.40 to0.60) 0.86 (1.41 to0.31)
Estruch et al. (olive) (42) 0.45 (1.72 to 0.82) 2.77 (1.67 to 3.87) 5.40 (16.57 to 5,77) 5.44 (8.13 to2.75) 1.65 (3.02 to0.28) 7.30 (13.06 to1.54) 0.85 (1.41 to0.29)
Paniagua et al. (ctr) (53) 0.18 (5.26 to 4.90)
Paniagua et al. (SF) (53) 8.64 (13.97 to3.31)
Lindeberg et al. (32) 2.60 (3.48 to 8.68) 0.03 (0.03 to 0.36)
Perez-Martinez et al. (wst) (60) 0.39 (5.20 to 5.98) 4.43 (22.34 to 13.48)
Perez-Martinez et al. (CHO) (60) 2.32 (3.27 to 7.91) 0.89 (18.47 to 16.70)
Papadaki and Scott (31) 7.74 (0.93 to 14.55) 7.09 (16.12 to 30.29)
Tuttle et al. (24) 2.00 (5.60 to 1.60) 41 (1.33 to 83.33) 1.00 (7.07 to 5.07) 0.00 (3.58 to 3.58)
(Continued on next page)
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March 15, 2011:1299–313 Mediterranean Diet and Metabolic Syndromestudies (39,42,43) reported a beneficial effect of an MD, as
compared with the control diet, and the overall adherence to
the MD was associated with lower systolic blood pressure
levels as compared with the control diet (Table 4). Heter-
ogeneity of the effect measures regarding systolic blood
pressure levels was observed [Cochran’s Q 31.18(15), p
.01, I2  51.8%].
With regard to diastolic blood pressure levels, no signif-
cant associations were observed in observational studies
Table 3). However, in clinical trials (3,060 subjects, 1,632
ssigned to an MD, and 1,436 assigned to a control diet) 5
tudies (39,41–43,51) reported a beneficial effect of an MD,
nd the overall effect suggested that adherence to the MD
as associated with lower diastolic blood pressure levels as
ompared with the control diet (Table 4). No heterogeneity
f the effect measures regarding blood pressure levels [Co-
hran’s Q  16.09(15), p  0.38, I2  6.7%] was observed.
GLUCOSE AND HOMEOSTATIC MODEL ASSESSMENT INSULIN
RESISTANCE LEVELS. Two observational studies (40,52) re-
ported a beneficial effect of close adherence to the MD as
compared with the control diet, and overall adherence to the MD
was associated with lower fasting glucose levels (Table 3). Het-
erogeneity of the effect measures regarding glucose levels
was observed [Cochran’s Q  65.05(7), p  0.001, I2 
9.2%]. Moreover, among the 17 clinical trials with 2,373
ubjects (1,357 assigned to an MD, and 1,139 assigned to a
ontrol diet), 6 studies (39,41–43,45,53) reported a benefi-
ial effect of an MD, as compared with the control diet.
verall, adherence to the MD was associated with lower
asting glucose levels as compared with the control diet
Table 4). Heterogeneity of the effect measures regarding
lucose levels was observed [Cochran’s Q  77.49(22), p 
.001, I2  71.6%].
Two observational studies with 3,042 subjects evaluated the
role of the MD on Homeostatic Model Assessment insulin
resistance (HOMA-IR) levels (40,52). Both studies reported a
beneficial effect of close adherence to the MD on HOMA-IR
levels, as compared with low adherence (Table 3). Hetero-
geneity of the effect measures regarding HOMA-IR levels
[Cochran’s Q  135.69(2), p  0.001, I2  98.5%] was
bserved. In addition, 10 clinical trials with 1,742 subjects
1,031 assigned to a MD and 711 to a control diet),
xamined the relationship between adherence to the MD
nd HOMA-IR. Six studies (30,39,41,42,44,51) reported
beneficial effect of a MD, as compared with the control
iet. Overall, adherence to the MD was associated with
ower HOMA-IR levels as compared with the control diet
Table 4). Heterogeneity of the effect measures regarding
OMA-IR levels [Cochran’s Q  118.06(12), p  0.001,
2  89.8%] was observed.
ensitivity analysis. Heterogeneity of the effect sizes of
D on MS as well as its components has already been
eported in the preceding text. Studies included in the
resent meta-analysis varied in some characteristics withregard to their design. The meta-analysis of clinical trialsCo T S S R B B B E A E E C Da
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Mediterranean Diet and Metabolic Syndrome March 15, 2011:1299–313revealed the beneficial role of the MD on MS, whereas
results from observational studies (cross-sectional and
prospective) showed a protective but not significant trend
(Fig. 2). Moreover, the heterogeneity found regarding the
overall effect of diet on MS was not attributed to the weight
of each study.
However, heterogeneity was also observed with regard to
the effect of diet on MS components. Specifically, differ-
ences were revealed with regard to: location of the studied
population (i.e., Mediterranean or non-Mediterranean
countries), sample size, duration of the intervention, en-
couraging of lifestyle changes, as well as trial quality. In
particular, in studies conducted in Mediterranean countries,
the effect of diet was significant with regard to all MS
components except for weight circumference, whereas in
studies not located in the Mediterranean region the effect of
diet was not associated with any of the MS components;
similarly, studies with intervention duration more than 3
months showed significant results for all the components
studied except for waist circumference, whereas clinical
trials with a 3-month intervention showed significant
esults only with regard to diastolic blood pressure and
lucose levels. Moreover, all studies with sample size above
he median (i.e., n 66) presented significant associations
etween diet and all the MS components, whereas studies
ith 66 participants did not show any significant associ-
tions. Studies also encouraging physical activity showed
ignificant associations with regard to all the components
tudied, except waist circumference; however, studies focus-
ng only on dietary intervention showed significant associ-
tions only with regard to blood pressure and glucose levels.
linical trials of high quality showed significant results
etween diet and all the components studied, except for
aist circumference, whereas clinical trials with low quality
howed significant results only with regard to diastolic blood
ressure and glucose levels (Table 5). Furthermore, when
he control diets were categorized (where this was possible)
nto “low-fat diet” (i.e., 30% fat),“usual treatment” type
i.e., no further dietary advice apart from that of hospital
ietitians or written advice), “high saturated fat diet” (i.e.,
aturated fat 20%), the subgroup meta-analysis showed
hat MD was associated with beneficial effects, as compared
ith the “low-fat diet” (with regard to HDL cholesterol,
riglycerides, systolic and diastolic blood pressure, glucose
evels) as well as with the “usual dietary recommendations”
with regard to HDL cholesterol and triglyceride levels).
iscussion
he present meta-analysis, performed in 50 studies, with an
verall incorporated population of approximately one-half
illion subjects, revealed the beneficial effect of the MD,
ith regard to not only the MS but also its individual
omponents, namely waist circumference, HDL cholesterol
evels, triglyceride levels, blood pressure levels, and glucoseetabolism. The significant heterogeneity observed mainly Se T
C D P P S
D
at
a A
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March 15, 2011:1299–313 Mediterranean Diet and Metabolic Syndromeon the effect of the MD on MS components was partially
attributed to the location of studies (i.e., Mediterranean or
not), the intervention duration, the number of the partici-
pants, and the quality of the studies. To the best of our
knowledge, this is the first work that has systematically
assessed, through meta-analysis, the role of the MD on MS
and its components.
The MD is one of the most known and well-studied
dietary patterns, which has been shown to be associated
with human health, especially decreased mortality from all
causes, lower risk for cardiovascular disease, and cancer (8);
it is also exerting a beneficial role with regard to type 2
diabetes and obesity (9,10). The results of the present
meta-analysis add to the existing knowledge, because they
indicate that adherence to the MD has a positive effect on
human health through different ways. The MD has a
beneficial effect on abdominal obesity, lipids levels, glucose
metabolism, and blood pressure levels, all the components
of the MS, which are also risk factors for the development
of cardiovascular disease, insulin resistance, and diabetes.
The antioxidant and anti-inflammatory effects of the MD as
a whole as well as the effects of the individual components
of the MD and specifically olive oil, fruits and vegetables,
whole grains, and fish could offer a possible explanation for
the aforementioned findings (9,11–15).
At this point it should be mentioned that abdominal
obesity is one of the main causes for the appearance of all
the components of the MS, because adipose tissue plays an
important role in lipid and glucose metabolism and is
responsible for the production of various cytokines influenc-
ing the development of the syndrome (54). The present
meta-analysis based on results from both observational
studies and clinical trials revealed the beneficial effect of the
MD with regard to central obesity.
Furthermore, results from studies conducted in Mediter-
ranean countries showed more prominent effects of the
Mediterranean-type dietary pattern, possibly due to the easy
access of consumers to the Mediterranean products. Never-
theless, these results could be attributed to other potential
confounders such as genetics or environmental factors (i.e.,
physical activity; food sources, enrichment, contamination).
In addition results of the present meta-analysis suggested
that adherence to the MD coupled with physical activity has
even more beneficial effects, showing the significant role of
an active lifestyle for the prevention of the MS components.
Finally, studies of high quality, longer intervention dura-
tion, and higher number of participants showed more
prominent results—a fact that can be attributed to the
crucial role of the design of a study.
Practical implications. The prevalence of the MS has
drastically increased during recent years and is very unlikely
to decrease, unless drastic measures are applied. For the
delay and prevention of its development, emphasis should
be placed on modifiable lifestyle factors. However, in spite
of efforts to promote a healthy lifestyle and encourage a
healthier diet and increase physical activity, dietary habits inthe developed world and in some developing countries are
changing toward the opposite direction. Even around the
Mediterranean basin, consumption of fat, meat, eggs, dairy
products, and sugar has increased, and consumption of
cereals, legumes, vegetables, and seafood has decreased.
Therefore, encouraging adherence to the MD might be a
solution to the problem, because the foods comprising this
dietary pattern—apart from its various health benefits—are
tasty and it is easy to follow in the long-term.
Study limitations. Certain limitations of this study war-
rant consideration. The Mediterranean dietary pattern is
not homogeneous; however, the basic characteristics of this
diet were present in all of the included epidemiological
studies. In addition, the MD intervention varied between
the clinical trials in terms of hours of intervention, detail of
the recommendations given, and macronutrient composi-
tion of the diet. In most trials, the control diet was a low-fat,
high-carbohydrate diet (21,23,24,42,43,46,47,49,53,55–62),
a low-carbohydrate diet (49,63), a prudent diet (30,32), usual
patient treatment (22,64), American Diabetes Association diet
(45), receiving general healthy dietary information
(27,29,31,39,41), high-saturated-fat diet (30,34,46,47,53,58–61),
or less counselling on an MD prescription (51). In 9 trials,
MD was part of a lifestyle intervention comprising exercise
(24,32,43) or a structured plan (smoking cessation, exercise,
stress management) (21,22,29,39,41,45). Moreover, signif-
icant heterogeneity is present in our analysis, which intro-
duces a warning about the generalization of the present
results. More cohort studies evaluating the role of the MD
on MS are needed.
Conclusions
The results of the present meta-analysis suggest that adher-
ence to the Mediterranean dietary pattern was associated
with lower MS prevalence and progression. Moreover,
greater adherence to this traditional dietary pattern was
associated with favorable effects on the MS components.
These results are of considerable public health importance,
because this dietary pattern can be easily adopted by all
population groups and various cultures (65) and cost-
effectively serve for the primary and secondary prevention of
the MS and its individual components.
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